Janney Montgomery Scott LLC Raises Position in Icon Plc $ICLR

Janney Montgomery Scott LLC lifted its position in Icon Plc (NASDAQ:ICLR) by 53.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,659 shares of the medical research company’s stock after acquiring an additional 12,717 shares during the period. Janney Montgomery Scott LLC’s holdings in Icon were worth $4,057,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Sanctuary Advisors LLC lifted its stake in Icon by 1.1% in the 4th quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock worth $899,000 after purchasing an additional 56 shares in the last quarter. Geneos Wealth Management Inc. grew its position in shares of Icon by 11.5% in the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after purchasing an additional 56 shares in the last quarter. New Wave Wealth Advisors LLC grew its position in shares of Icon by 5.1% in the fourth quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock valued at $270,000 after purchasing an additional 72 shares in the last quarter. Signaturefd LLC increased its holdings in shares of Icon by 12.6% in the fourth quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock valued at $117,000 after purchasing an additional 72 shares during the last quarter. Finally, 1900 Wealth Management LLC increased its holdings in shares of Icon by 4.4% in the fourth quarter. 1900 Wealth Management LLC now owns 2,430 shares of the medical research company’s stock valued at $443,000 after purchasing an additional 103 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Analyst Ratings Changes

ICLR has been the subject of several analyst reports. Weiss Ratings cut Icon from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, May 29th. Citigroup lifted their price target on Icon from $140.00 to $165.00 and gave the stock a “neutral” rating in a report on Thursday, June 25th. Mizuho upped their price objective on shares of Icon from $180.00 to $190.00 and gave the company an “outperform” rating in a report on Friday, June 26th. DA Davidson set a $164.00 price objective on shares of Icon in a research report on Monday, June 1st. Finally, Royal Bank Of Canada raised shares of Icon from a “sector perform” rating to an “outperform” rating and lifted their target price for the stock from $126.00 to $185.00 in a research note on Thursday, June 25th. Nine equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $173.19.

Icon Trading Down 1.4%

ICLR stock traded down $2.33 during midday trading on Tuesday, hitting $168.61. 32,549 shares of the company’s stock were exchanged, compared to its average volume of 1,502,293. Icon Plc has a 1-year low of $66.57 and a 1-year high of $211.00. The company has a current ratio of 1.14, a quick ratio of 1.14 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $12.91 billion, a PE ratio of 30.07, a P/E/G ratio of 8.49 and a beta of 1.22. The business has a 50-day simple moving average of $136.63 and a two-hundred day simple moving average of $137.46.

Icon (NASDAQ:ICLR) last announced its quarterly earnings results on Tuesday, June 23rd. The medical research company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.43 by $0.07. The business had revenue of $2.03 billion for the quarter, compared to analyst estimates of $1.98 billion. Icon had a return on equity of 8.73% and a net margin of 5.35%.The company’s quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.43 EPS. On average, sell-side analysts predict that Icon Plc will post 9.43 EPS for the current fiscal year.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.